Batten disease conference heads to Boston for the first time

Boston will host the NCL Translational Science and Therapeutics Conference for the first time Nov. 11-13, bringing international scientists, clinicians, industry researchers and patient advocates together to advance Batten disease research and therapeutic development. Organizers are also seeking new sponsorships from health systems, biotech and pharmaceutical companies, universities and foundations.

Why it matters: - The Boston-area meeting puts rare disease research in front of the region’s academic, biotech and medical communities. - The conference is designed to speed collaboration on Batten disease, also known as neuronal ceroid lipofuscinoses, and on related lysosomal research that could affect broader therapeutic development. - Sponsorship support can help sustain an international forum that connects academic research, clinical care, drug development and patient advocacy.

What happened: - The NCL Translational Science and Therapeutics Conference will be held Nov. 11-13, 2026, at the Marriott Boston Quincy in Quincy, Massachusetts. - This is the first time the Boston area has hosted the conference. - Our Promise to Nicholas Foundation is hosting the event. - The meeting is the ninth conference in the series over 16 years. - The event will bring together international scientists, clinicians, industry researchers and patient advocates.

The details: - Conference sessions will focus on emerging discoveries, drug development challenges and collaboration that can move research toward clinical treatments. - Dr. Jill Weimer and the Weimer Lab at Sanford Research are receiving special recognition for scientific leadership. - Batten disease includes a group of rare, inherited neurodegenerative disorders known as neuronal ceroid lipofuscinoses, or NCLs. - Research in NCLs connects to lysosomal biology, cellular function, neuroscience and therapeutic development beyond the disease itself. - Supporters listed for the conference include BioMarin Pharmaceutical, Scenic Biotech, Azafaros, Sanford Health in South Dakota, Eastern Bank and Bedford Gastroenterology. - The conference also recognizes support from Beyond Batten Disease Foundation, Noah’s Hope & Hope 4 Bridget Foundation and Children’s Brain Diseases Foundation, along with family foundations.

Between the lines: - The conference series has served as a targeted meeting place for experts spread across institutions and countries for 16 years. - Its move into Greater Boston signals an effort to deepen ties with one of the country’s strongest life sciences and academic hubs. - Organizers are positioning the meeting as both a scientific exchange and a fundraising opportunity for institutions with an interest in rare disease innovation.

What's next: - Our Promise to Nicholas Foundation is inviting healthcare systems, biotechnology and pharmaceutical companies, universities and philanthropic foundations to sponsor the conference. - Organizers say sponsorship can help institutions advance research, education and rare disease care goals. - The foundation is also inviting companies and foundations to engage with investigators working to translate scientific findings into better treatments. - Bedford Gastroenterology says it supports the effort and is encouraging other organizations to join the existing sponsors and scientific partners.

The bottom line: - Boston gets its first turn hosting a long-running Batten disease conference, with the goal of turning scientific exchange into faster progress toward treatments.